Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

SPL028

From Wikipedia, the free encyclopedia

Pharmaceutical compound
SPL028
Clinical data
Other namesSPL-028; α,α-Dideutero-N,N-dimethyltryptamine;N,N-D2-dimethyltryptamine; D2-DMT
Routes of
administration
Intravenous injection,intramuscular injection[1]
Drug classSerotonin receptor modulator;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Identifiers
PubChemCID
ChemSpider
Chemical and physical data
3D model (JSmol)
  • [2H]C([2H])(CC1=CNC2=CC=CC=C21)N(C)C
  • InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3/i8D2
  • Key:DMULVCHRPCFFGV-MGVXTIMCSA-N

SPL028, orSPL-028, also known asα,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is apsychedelic drug of thetryptamine family which is under development for the treatment ofdepressive disorders.[2][3][4][5] It is theanalogue ofdimethyltryptamine (DMT) in which theα carbon has been dideuterated.[2][6] SPL028'sroute of administration isintravenous injection orintramuscular injection.[1]

The drug shows similarpharmacodynamics as DMTin vitro.[2][6] Relatedly, SPL028 generalized with DMT in rodentdrug discrimination tests.[6][7] On the other hand, SPL028 differs from DMT in terms ofpharmacokinetics; it is more resistant tometabolism and shows a prolongedduration.[2][6][7] In aphase 1clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.[8]

SPL028 was originated by Small Pharma and is under development byCybin.[4] Small Pharma was acquired by Cybin in 2023.[9] As of February 2024, SPL028 is in phase 1 clinical trials.[4]

See also

[edit]

References

[edit]
  1. ^abMarino D (15 February 2023)."First Subject Dosed in Small Pharma's First-in-Human Phase 1 Clinical Trial".Drug Development and Delivery. Retrieved27 July 2025.
  2. ^abcdLayzell M, Rands P, Good M, Joel Z, Cousins R, Benway T, et al. (14 September 2023)."Discovery and In Vitro Characterization of SPL028: Deuterated N , N -Dimethyltryptamine".ACS Medicinal Chemistry Letters.14 (9):1216–1223.doi:10.1021/acsmedchemlett.3c00143.ISSN 1948-5875.PMC 10510671.PMID 37736183.
  3. ^Kargbo RB (8 September 2022)."Application of Deuterated N , N -Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders".ACS Medicinal Chemistry Letters.13 (9):1402–1404.doi:10.1021/acsmedchemlett.2c00354.ISSN 1948-5875.PMC 9465894.PMID 36105328.
  4. ^abc"SPL 028".AdisInsight. 16 February 2024. Retrieved27 July 2025.
  5. ^"Delving into the Latest Updates on SPL-028 with Synapse".Synapse. 14 June 2025. Retrieved27 July 2025.
  6. ^abcdGood M, Cheetham S, Davis I (2023)."The International BNA 2023 Festival of Neuroscience: Preclinical characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders".Brain and Neuroscience Advances.7: 77.doi:10.1177/23982128231180246.ISSN 2398-2128.PMC 10236260.The PK and pharmacology of SPL028 (α,α-bisdeutero-N,N-dimethyltryptamine (D2DMT) fumarate) [di-deuterated analogue of SPL026] was investigated through a series of preclinical studies. [...] SPL028 exhibited prolonged PK and pharmacodynamic effects compared to SPL026. In vitro & in vivo studies found the metabolic stability of SPL028 increased relative to SPL026. The in vitro & ex vivo receptor profiles of SPL028 and SPL026 were equivalent. These findings were consistent with drug discrimination study: rats were not able to distinguish SPL028 from SPL026.
  7. ^abGood M, Joel Z, Cheetham S, Davis I, Rowley H, James E, et al. (April 2023).In vivo characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders(PDF). British Neuroscience Association 2023 (BAN2023).
  8. ^"Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028".Nasdaq. 5 April 2024. Retrieved27 July 2025.
  9. ^Alpha P (28 August 2023)."Cybin Set to Acquire British DMT Drug Developer Small Pharma".Psychedelic Alpha. Retrieved27 July 2025.

External links

[edit]


Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
α-Ketotryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=SPL028&oldid=1324540140"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp